Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


mimi.bogale@ndorms.ox.ac.uk

Mimi Bogale

MSc in Biomedical Sciences

Clinical Trial Manager

I joined NDORMS in December 2020 as a Clinical Trial Manager for the OPTIMISE trial within the  Experimental Medicine and Rheumatology (EMR) group. Currently, I am in charge for the successful set-up and delivery of the BALANCE trial. BALANCE is a multi-centre, observational cohort prospective study. The aim of the study is to explore the impact of Bimekizumab (IL17A&F inhibitor) on non-invasive measures of liver disease (in psoriatic disease) and links to underlying pathological mechanisms.

As a trial manager, I am responsible for the day-to-day and overall management of clinical research studies, from design and set-up to close-out. Experienced in study document/ database (REDCao) development, site set up, overseeing timelines and budgets, and ensuring compliance with regulatory and ethical standards. 

Prior to joining NDORMS, I worked as a Clinical Study Coordinator in the Department of Rheumatology of the Catholic University Hospitals Leuven. (KU Leuven).  Here, I worked on the safety and efficacy of phase II- IV drug and strategy trials in patients with Psoriatic arthritis (PsA), Rheumatoid arthritis (RA), and Ankylosing spondylitis (AS). 

I attended Catholic University of Leuven (KU Leuven) and achieved both my BSc. and MSc degree in Biomedical Sciences. Studying Biomedical Sciences was an excellent choice since I am interested in the human body and its disorders. Being fascinated by the final phases of the drug development process, I pursued my career in the field of clinical research.